X Linked Hypophosphatemia News and Research

RSS

Calcified Tissue International announces top 10 most impactful papers of 2019

Calcified Tissue International and Musculoskeletal Research is among the leading peer-reviewed journals publishing original preclinical, translational, and clinical research as well as expert reviews in the bone and musculoskeletal field.

13 Jun 2021

New drug could alleviate symptoms of rare musculoskeletal condition

A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.

20 May 2019

Inherited form of rickets improves more with new injectable medicine than conventional therapy

Burosumab, a new injectable medicine to treat X-linked hypophosphatemia (XLH), an inherited form of rickets, demonstrates superior improvements in rickets and other outcomes compared with conventional therapy in an international, phase 3 clinical trial in children.

25 Mar 2019

$Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR$

Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

New research on calcium supplements and vitamin D, risk of fractures in older men, and the new culprit in bone fractures, weak muscles, and more will be released at the American Society for Bone and Mineral Research (ASBMR) 2013 Annual Meeting in Baltimore, the largest scientific meeting in the world on bone and mineral metabolism.

7 Oct 2013

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

...

4 Sep 2013

Osteopontin plays a role in X-linked hypophosphatemia

Diagnosed in toddlers, X-linked hypophosphatemia (XLH) is the most common form of heritable rickets, in which soft bones bend and deform, and tooth abscesses develop because infections penetrate soft teeth that are not properly calcified. Researchers at McGill University and the Federal University of Sao Paulo have identified that osteopontin, a major bone and tooth substrate protein, plays a role in XLH. Their discovery may pave the way to effectively treating this rare disease.

21 Feb 2013

X Linked Hypophosphatemia News and Research

Calcified Tissue International announces top 10 most impactful papers of 2019

New drug could alleviate symptoms of rare musculoskeletal condition

Inherited form of rickets improves more with new injectable medicine than conventional therapy

Research on calcium supplements and vitamin D, risk of fractures and more to be released at ASBMR

Ultragenyx, Kyowa Hakko Kirin To Develop Rare Bone Disease-Fighting Mab

Osteopontin plays a role in X-linked hypophosphatemia

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News